<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="322">
  <stage>Registered</stage>
  <submitdate>29/08/2005</submitdate>
  <approvaldate>31/08/2005</approvaldate>
  <actrnumber>ACTRN12605000247673</actrnumber>
  <trial_identification>
    <studytitle>Second generation intervention research in the pre-psychotic phase of illness in schizophrenia and related psychoses</studytitle>
    <scientifictitle>Prevention or delay of onset of psychosis in an 'ultra high risk' group:  A comparison of risperidone and placebo in combination with intensive psychological treatment</scientifictitle>
    <utrn />
    <trialacronym>RIS-AUS-9</trialacronym>
    <secondaryid>RID-AUS-9</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Schizophrenia and other psychotic disorders</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Schizophrenia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Other mental health disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A comparison of the effectiveness of low-dose risperidone (0.5-2.0 mg/day) and intensive psychological treatment vs. placebo and intensive psychological treatment vs. placebo and a control psychological treatment in preventing or delaying the onset of psychosis in young people at risk of developing a psychotic illness:  A 12-month blinded, placebo-controlled, parallel groups treatment period followed by a 12-month follow-up period.</interventions>
    <comparator>Placebo and a control psychological treatment</comparator>
    <control>Placebo</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Prevention or delay of onset of psychosis.</outcome>
      <timepoint>At the end of the 12-month treatment period and the 12-month follow-up period</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Improvement in general psychopathology and functioning.</outcome>
      <timepoint>At the end of 12-month treatment period and the 12-month follow-up period.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Participants must meet 'ultra high risk' criteria as outlined in Yung, Phillips and McGorry (2004)  Treating Schizophrenia in the Prodromal Phase.  London: Taylor nd Francis.  Also, have not previously experienced psychotic episode, IQ &gt; 70, adequate English skills, and living in Melbourne metro area.</inclusivecriteria>
    <inclusiveminage>14</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>30</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Randomly generated via computer program, medication packaged by automated process, codes stored in locked cabinet and not revealed until trial completed</concealment>
    <sequence>Randomly generated via computer program in blocks</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>8/01/2000</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Janssen-Cilag Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress>Locked Bag 2070
North Ryde NSW 1670</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Janssen-Cilag Pharmaceuticals</fundingname>
      <fundingaddress>Locked Bag 2070
North Ryde
NSW 1670</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To investigate whether risperidone either alone or in combination with an intensive psychological treatment can delay or prevent the onset of an acute psychotic episode in young people thought to be at heightened risk of illness.  The secondary aim was to investigate whether the interventions were effective in reducing general pscyhopathology in the participants whilst improving functioning.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>PACE Clinic- Orygen Youth Health, NW Mental Health Program</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Prof Patrick McGorry</name>
      <address>Orygen Research Centre
Locked Bag 10
Parkville VIC 3052</address>
      <phone>+61 3 93422800</phone>
      <fax>+61 3 93422948</fax>
      <email>pmcgorry@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Barnaby Nelson</name>
      <address>Personal Assessment Crisis Evaluation (PACE) Clinic
Department of Psychiatry
ORYGEN Research Centre
University of Melbourne
c/- Locked Bag 10
Parkville VIC 3052</address>
      <phone>+61 3 93176300</phone>
      <fax>+61 3 93170533</fax>
      <email>Barnaby.Nelson@mh.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>